Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples
暂无分享,去创建一个
Andrew S. Kohlway | S. Spiegl-Kreinecker | J. Hainfellner | M. Preusser | C. Corless | M. Filipits | M. Bates | J. Weidler | A. Berghoff | E. Lai | Kriszten Kocmond
[1] K. Aldape,et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. , 2018, Neuro-oncology.
[2] G. Reifenberger,et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.
[3] M. Weller,et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. , 2015, Neuro-oncology.
[4] C. Marosi,et al. Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma , 2013, Clinical neuropathology.
[5] G. Reifenberger,et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly , 2012, International journal of cancer.
[6] Didier Frappaz,et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[7] M. Sanson,et al. Comparative assessment of 5 methods (methylation‐specific polymerase chain reaction, methylight, pyrosequencing, methylation‐sensitive high‐resolution melting, and immunohistochemistry) to analyze O6‐methylguanine‐DNA‐methyltranferase in a series of 100 glioblastoma patients , 2012, Cancer.
[8] G. Reifenberger,et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[9] M. Weller,et al. Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma , 2012, PloS one.
[10] R. Lothe,et al. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR , 2012, Journal of Translational Medicine.
[11] G. Reifenberger,et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas , 2011, International journal of cancer.
[12] Stephan Saikali,et al. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods , 2010, Journal of Neuro-Oncology.
[13] J. Hainfellner,et al. Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. , 2008, Clinical neuropathology.
[14] J. Schramm,et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. , 2007, The Journal of molecular diagnostics : JMD.
[15] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.